Daniel Esgardo Rangel Barón: $200K Saved With First-Line Docetaxel for Prostate Cancer

For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.
Medscape Medical News
View Source

Related Post